Respiratory tract infections (RTIs) are a huge burden in terms of mortality and morbidity worldwide. To improve the management of the bacterial infections of the respiratory tract, the institution of an appropriate antimicrobial t...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TAILORED-TREATMENT
DEVELOPMENT OF TAILORED ANTIMICROBIAL TREATMENT REGIMENS AND...
8M€
Cerrado
RAPID
Rapid Antimicrobial susceptibility testing and phylogenetic...
150K€
Cerrado
PLEC2021-007972
Amplificación de la polimerasa en combinación con un array e...
200K€
Cerrado
MAGTEST
MAGTEST Simple and specific next generation lab on a chip i...
71K€
Cerrado
BacterOMIC
Intelligence for precision therapies against antimicrobial r...
3M€
Cerrado
AntibioDx
AntibioDx A groundbreaking in vitro diagnostic device with...
71K€
Cerrado
Información proyecto C4L
Líder del proyecto
CORIS BIOCONCEPT SPRL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Respiratory tract infections (RTIs) are a huge burden in terms of mortality and morbidity worldwide. To improve the management of the bacterial infections of the respiratory tract, the institution of an appropriate antimicrobial therapy as soon as possible has also been shown to be a key element for reducing morbidity and mortality. The aim of our project is to develop a panel of dedicated rapid diagnostic tests to allow the medical staff to link antibiotic prescription on evidence-based diagnosis. In our 3 year project, combining the Multiplex Ligation-dependent Probe Amplification (MLPA) and microfluidic technologies will allow to address the question of viral or bacterial origin. In the case of a bacteria, a second step will allow to identify which bacteria is of interest with its virulence factors and resistance mechanisms. This new tool will be developed for efficient use in clinical settings in order to allow for a better antibiotic resistance management. Several direct impacts will be observed either on public health (decrease of antibiotic pressure), efficiency of treatment for patients (decrease of infectivity and speed in accurate treatments), for diagnostic laboratories (improve in turn around time), for SMEs (better competitiveness) and more generaly on technological innovations.